Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 118 filers reported holding Y-MABS THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $79,548 | -18.1% | 14,596 | +2.0% | 0.00% | – |
| Q2 2023 | $97,138 | +35.5% | 14,306 | 0.0% | 0.00% | – |
| Q1 2023 | $71,673 | +2.7% | 14,306 | 0.0% | 0.00% | – |
| Q4 2022 | $69,813 | -68.0% | 14,306 | -5.2% | 0.00% | -100.0% |
| Q3 2022 | $218,000 | -4.4% | 15,096 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $228,000 | +71.4% | 15,096 | +35.3% | 0.00% | – |
| Q1 2022 | $133,000 | -26.5% | 11,156 | 0.0% | 0.00% | – |
| Q4 2021 | $181,000 | -42.4% | 11,156 | +1.2% | 0.00% | -100.0% |
| Q3 2021 | $314,000 | -15.6% | 11,019 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $372,000 | +39.3% | 11,019 | +24.6% | 0.00% | 0.0% |
| Q1 2021 | $267,000 | -38.1% | 8,845 | +1.5% | 0.00% | 0.0% |
| Q4 2020 | $431,000 | +28.7% | 8,715 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $335,000 | -4.8% | 8,715 | +7.0% | 0.00% | 0.0% |
| Q2 2020 | $352,000 | – | 8,145 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sofinnova Investments, Inc. | 2,104,278 | $55,890,000 | 4.98% |
| SCOPIA CAPITAL MANAGEMENT LP | 1,587,566 | $42,166,000 | 0.81% |
| DC Investments Management, LLC | 25,000 | $664,000 | 0.45% |
| Monashee Investment Management LLC | 67,800 | $1,801,000 | 0.38% |
| Avoro Capital Advisors LLC | 310,000 | $8,234,000 | 0.38% |
| Cormorant Asset Management, LP | 200,000 | $5,312,000 | 0.34% |
| PURA VIDA INVESTMENTS, LLC | 22,350 | $594,000 | 0.12% |
| Artal Group S.A. | 150,000 | $3,984,000 | 0.10% |
| OXFORD ASSET MANAGEMENT LLP | 59,122 | $1,556,000 | 0.03% |
| Point72 Hong Kong Ltd | 3,252 | $86,000 | 0.03% |